Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Perspectives on 2018 Pipeline

Posted by Matt Breese on Feb 27, 2018

The rise of CAR-T and other gene therapies, newly identified oncology targets and next-generation sequencing will shape the pipeline for 2018.
 
With the first CAR T-cell therapy approved, this new form of immunotherapy has a bright future. Yet drug companies also need to respond to worrisome side effects, such as severe cytokine release syndrome.
 
Read More

Topics: Specialty, Industry Trends, Product Release

Trends That Matter for Promising Drugs in 2018

Posted by Matt Breese on Feb 22, 2018

FDA’s Center for Drug Evaluation and Research (CDER) approved 46 new drugs in 2017, more than doubling the number of novel medications approved in 2016.

Among the drugs that have been recently launched or will be launched soon, Dupixent, Ocrevus and Imfinizi top the most promising drugs in 2018, according to IgeaHub, a pharmaceutical club for industry influencers. 

Read More

Topics: Industry Trends, Product Release, Branding & Marketing

Perspectives on NASH Market

Posted by Matt Breese on Feb 20, 2018

Non-alcoholic Steatohepatitis (NASH), the severest form of non-alcoholic fatty liver disease (NAFLD), is expected to become the leading cause of liver transplantation by 2020 in the United States. This untapped market might become the next big market in the metabolic disorders segment.  
 
Currently, lifestyle modifications, such as diet and regular exercise, are the main initial therapeutic step. Bariatric surgery is considered the last option, which improves histology and causes massive weight loss. 
 
Read More

Topics: Industry Trends, Market Access, Branding & Marketing

MMIT Reality Check on Hereditary Angioedema (Feb 2018)

Posted by Matt Breese on Feb 19, 2018

According to our recent payer coverage analysis for hereditary angioedema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Trends That Matter for HIV

Posted by Matt Breese on Feb 15, 2018

In our weekly Trends that Matter series, we provide infographics, articles and recent news from health care influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is HIV. 

According to our recent payer coverage analysis for HIV, combined with news from key health care influencers, market access is shifting in this drug landscape. 

Read More

Topics: Specialty, Industry Trends

Perspectives on OTC Pharma Packaging

Posted by Matt Breese on Feb 13, 2018

As the U.S. reported sales of $45.8 billion for over-the-counter (OTC) medicine in 2016, manufacturing and packaging firms saw great opportunity to capitalize in the space, according to Pharmapack. 
 
To seize the opportunity, OTC makers need to understand the changing market dynamics: growing health care costs, aging populations, demand for more affordable health care and increasing M&A activity.  
 
Read More

Topics: Industry Trends, Market Access, Branding & Marketing

MMIT Reality Check on IVIG (Feb 2018)

Posted by Matt Breese on Feb 9, 2018

According to our recent payer coverage analysis for immune globulin treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Trends That Matter for Product Launch

Posted by Matt Breese on Feb 8, 2018

When launching new products, pharmaceutical companies should bring an outcome rather than just a product to market, according to a new study from the professional services company Accenture.

Findings from the study, titled "Product Launch: The Patient Has Spoken," suggest that a medication's benefits are the key factors patients consider when looking at new products. More than 69% of patients think the benefits are more important than the brand of the product. 

Read More

Topics: Product Release, Branding & Marketing

Perspectives on Triggered Messages

Posted by Matt Breese on Feb 6, 2018

Data is nothing new to pharmaceutical marketers, who have become accustomed to using data to generate triggered messages, a near-real-time reaction to certain events or decisions, to their providers.
 
The next step is to go beyond simple messaging and personally tailor the message across varied platforms by using analytics and predictive tools, says Jose Ferreira, vice president of customer experience and data management at CMI/Compas. 
 
Read More

Topics: Data & Analytics, Branding & Marketing

MMIT Reality Check on HIV (Feb 2018)

Posted by Matt Breese on Feb 2, 2018

According to our recent payer coverage analysis for HIV treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing